Junshi Biosciences enters licensing agreement with Fosun Wanbang for roconkibart
UNVERIFIED·Primary source · Financial Post
Junshi Biosciences granted Fosun Wanbang rights to develop and commercialize roconkibart in Greater China.
The deal includes an upfront payment of RMB 215 million and potential milestone payments of up to RMB 1.125 billion.
Roconkibart is an anti-IL-17A monoclonal antibody for autoimmune diseases like psoriasis.
Key Facts
01
01 — What / Thesis
Junshi Biosciences enters licensing agreement with Fosun Wanbang for roconkibart
02
02 — Who / Subject
Junshi Biosciences, Fosun Wanbang
03
03 — Where / Locus
Greater China
04
04 — When / Temporality
July 01, 2026
AI Verification Note
This article is generated by cross-referencing multiple sources and official announcements. Parts relying solely on testimony or reporting are reflected in the confidence score; content and assessment are updated as new information is confirmed.
